AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05646511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOXIRI
Description: Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks, if the initial dose of irinotecan 150 mg/m²/day is tolerated, the dose can be increased to 200 mg/m²/day from the second cycle
Study NCT06461741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Dual-task EMG Biofeedback Training (EMG-BF)
Description: The intervention is an exercise training that is facilitated by feedback derived from electrical muscle activity measured through electromyography (EMG). An EMG Biofeedback software uses a machine learning algorithm to identify the desired movements and reinforce them by displaying feedback on a computer monitor in the form of videogame control. The EMG acquisition hardware must have at least 4 sensor channels and a sampling rate of >1KHz. Other than these specifications, any generic EMG amplifier can be used. The effect of the device is therefore primarily defined by the software. An in-depth description of the software and hardware systems is published in the cites study, An EMG-Based Biofeedback System for Tailored Interventions Involving Distributed Muscles. In this trail is the Explore+ ExG amplifier which is sold by Mentalab.
Study NCT06461741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Balance Exercise Training (BAL-EX)
Description: This intervention is a time-matched active comparator for the EMG-BF intervention. A sequence of seven traditional, balance exercises, taking 1-3 minutes each, is repeated for a total of 30 minutes on each of 18 sessions in the 6-week intervention period. The exercises are ones that challenge the coordination and strength of postural muscles in the presence of various vestibular stimuli. The specific exercises are described in the Arm description.
Study NCT06098586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-managed exercise therapy program
Description: Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
Study NCT06098586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial wrist denervation
Description: AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
Study NCT05121207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Terahertz scanning
Description: Short scans using Terahertz device
Study NCT06321172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Bike
Description: Six months of FES-cycling trainings twice a week is performed for each pilot. Each session includes at most 30 minutes of stimulation. At the beginning of the training period, a conditioning phase is performed until the pilot reaches pedalling autonomy. This period is also used to define the stimulation parameters (minimum and maximum values of current intensity and pulse width), reference cadence and gear, specific for the ability of each pilot. Then the training period starts and is performed indoor, setting the resistance of the smart trainer at 10% for all the participants. The sessions are organized as follows: a 3-minute warmup followed by four sets of 6 minutes of pedalling and a 3-minute cool down.
Study NCT05144737 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Diabetes Prevention Program
Description: The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
Study NCT06458738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Printable denture base material
Description: The newly developed printable denture base material will be used for the production of dentures.
Study NCT05939544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient
Description: Milk Fat Globule Membrane-enriched Powdered Ingredient
Study NCT05939544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control (Placebo) Powdered Ingredient
Description: Placebo Comparator: Control (Placebo) Powdered Ingredient
Study NCT04792099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
Study NCT04792099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula
Description: After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
Study NCT06024382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: twin block
Description: 2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
Study NCT06024382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: twin block combined with low level laser
Description: 2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
Study NCT06506942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve through a transcatheter approach
Study NCT06458244 — intervention group
Intervention type: PROCEDURE
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Allogeneic Hematopoietic Stem Cell Transplantation
Study NCT06458244 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy for AML consolidation treatment
Study NCT05767086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin releasing hormone antagonist (Cetrotide)
Description: clinical pregnancy rates
Study NCT05767086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate (Tarlusal)
Description: clinical pregnancy rates
Study NCT05767086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: clinical pregnancy rates
Study NCT05709327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)
Description: Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
Study NCT06332339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 16055 NFL delta Gly4 trimer
Description: 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)
Study NCT06218186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device: Wesper Lab Home Sleep Test
Description: Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
Study NCT06332339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571
Description: 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)
Study NCT06332339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-Env145NFL, 5 x 108 viral particles (vp)
Description: to be administered intranasally (IN) (0.07 mL into 1 nostril)
Study NCT05916937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab 300 mg every four weeks
Description: Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.
Study NCT05916937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab 300 mg every six weeks
Description: Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.
Study NCT05810597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05810597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Dose Pen
Description: Used to administer tirzepatide SC
Study NCT05810597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-use Prefilled Pen
Description: Used to administer tirzepatide SC
Study NCT05136027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Low-intensity interval training and resistance exercise
Study NCT04825600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: anti-Toxoplasma gondii IgG and IgM dosage
Description: blood sample performed to check the toxoplasma serological diagnosis
Study NCT04825600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cellular test
Description: blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
Study NCT06568575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experiment of music
Description: Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by exercise program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes.
Study NCT06568575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experiment of exercise
Description: Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by music program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes. The music experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time, and a total experiment time of 1420 minutes. Examples of songs：Everytime We Touch- Cascada (115 bpm), Beat It - Michael Jackson (120 bpm), Viva La
Study NCT04908046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
Description: Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly.
Study NCT04882046 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
Study NCT04882046 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: collection of socio-demographic, clinical and biological data.
Study NCT05021081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRP-200
Description: JJVC Investigational Contact Lens
Study NCT05021081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day
Description: JJVC Marketed Contact Lens
Study NCT04697056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized Monoclonal Antibody
Study NCT04697056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06634537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Comparator: insoles hard, soft and barefoot
Description: Primary Outcome Measure:~1. Stabilometry The measurements were conducted University. To assess participants' balance, the anthropometric position of the protocol proposed by the International Society for the Advancement of Cineatropometry (ISAK) was assigned: participants placed their mi Frankfort; the upper limbs remained relaxed throughout the body, with palms facing forward and thumbs separated from the rest of the toes, and were barefoot with feet externally rotated f 30 degrees and with a heel distance of 4cm.~The children were wearing sports costumes to contribute their free movement. For stabilometry data collection will use an inertial measurement instrument called Gyko® It is a state-of-the-art device that allows to measure an objective assessment of acceleration, angular velocity and with an acquisition frequency of 100Hz \[Time Frame: pre intervention, 3 months post intervention, 6 months post intervention\]
Study NCT04357353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: PRP will be used in the experimental arm.
Study NCT04357353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Sham Injection
Description: sham injection
Study NCT05807724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based fall-prevention strategy
Description: Written education material and Phone-Based Fall-Prevention Strategy
Study NCT06535763 — intervention group
Intervention type: OTHER
Intervention: professional caregiver
Description: Care professionals will be questioned using a self-administered Quality of Life at Work scale, as well as a second scale (before and after training, with one test per day for 3 consecutive working days) asking about the number of work situations involving behavioral disorders in the residents under their care, and how they use the HAPNeSS method to deal with these situations.~The effects of the HAPNeSS method on caregivers' professional practices (actions taken, performance of tasks, relations with residents, etc.) and their feelings on the subject, will be collected in two semi-structured interviews (with half the participants selected at random) conducted before and after the training course by the research team's occupational psychologist.
Study NCT05807724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-visit fall prevention strategy
Description: Written education material and Home visit-Based Fall-Prevention Strategy
Study NCT04929236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
Study NCT03803540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation via duodenal infusion
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: Olmesartan administered orally
Study NCT04905693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled Treprostinil (6 mcg/breath) administered QID
Study NCT04905693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Study NCT06268028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Discharge training
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine administered orally
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine administered orally
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indapamide
Description: Indapamide administered orally
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by subcutaneous (SC) injection
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by subcutaneous (SC) injection
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection
Study NCT06512519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second allogeneic stem cell transplantation
Description: 1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 ), cyclophosphamide (1g/m2/day, days -5 to -4)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)
Study NCT04837833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
Study NCT04580420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: Monthly dosing throughout study period
Study NCT05103332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilebesiran
Description: Zilebesiran administered by SC injection
Study NCT05858294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy programme
Description: This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
Study NCT06262555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial PDT peripheral lung tumor ablation
Description: Transbronchial lung tumor ablation with Photodynamic therapy
Study NCT06169293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-AM-WELL
Description: The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours.
Study NCT05117333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminder (information letter)
Description: Reminders
Study NCT05424380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3745417
Description: GSK3745417 will be administered
Study NCT06001762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4 and CDK6 inhibitor, tablet taken orally
Study NCT06001762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Selective estrogen receptor modulator, taken orally per institutional standard of care
Study NCT06001762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
Study NCT06001762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
Study NCT06001762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Steroidal aromatase inhibitor, taken orally per institutional standard of care
Study NCT06001762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
Study NCT05570630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAX-MOM COVID-19 Intervention
Description: The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
Study NCT05570630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard vaccine education and processes provided to patients by obstetric practices.